NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Clinical trial NCT07178730 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07178730
- Sponsor
- Women's Cancer Study Group GmbH
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-30
- Primary completion
- 2033-03-31
- Enrollment
- 765
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.